Donna A Wall
Donna A Wall
When selecting a cord blood unit for transplantation a transplant program must, in addition to considering HLA match and cell dose, know that the unit is potent, pure and will not transfer an infectious, hematologic or immunologic disease. ...
Where do we go from here? [0.03%]
接下来我们该怎么办？
Kanti R Rai
Kanti R Rai
Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia [0.03%]
诱导慢性淋巴细胞性白血病凋亡及克服耐药性的策略
Rong Chen,William Plunkett
Rong Chen
Chronic lymphocytic leukaemia (CLL) is characterised by the dependence on the overexpression of anti-apoptotic proteins to maintain their survival. Based on this biological context, a strategy for CLL therapy was proposed using inhibitors o...
Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches [0.03%]
慢性淋巴细胞性白血病的感染并发症：发病机制、感染范围及预防措施
Vicki A Morrison
Vicki A Morrison
Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL). The pathogenesis of infections in these patients is multifactorial, related to inherent immune defects an...
Bruce D Cheson
Bruce D Cheson
The availability of safe and effective monoclonal antibodies has revolutionised the treatment strategies for patients with chronic lymphocytic leukaemia (CLL). Alemtuzumab, the first antibody approved for these patients, induces responses i...
Erin Hertlein,John C Byrd
Erin Hertlein
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signalling pathway is constitutively active in a variety of cancers, including chronic lymphocytic leukaemia (CLL). The importance of this signalling pathway ide...
Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands [0.03%]
慢性淋巴细胞白血病中的干细胞移植——在变化的沙丘上安全行进
Simon Hallam,John G Gribben
Simon Hallam
There is no clear consensus regarding the optimal management of chronic lymphocytic leukaemia. Many patients are diagnosed at an advanced age and will die with chronic lymphocytic leukaemia, but of other unrelated causes. A significant mino...
Carol Moreno,Matthias Ritgen,Andy Rawstron
Carol Moreno
Among chronic lymphocytic leukaemia (CLL) patients who require therapy, their response to therapy is the most important prognostic factor, with a better response predicting longer progression-free and overall survival. In this context, pati...
Michael Hallek
Michael Hallek
Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence th...